Company news

Aquestive Therapeutics, Inc. news in 2022

Aquestive Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

December 21, 2022

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

November 28, 2022

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

November 8, 2022

Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

October 31, 2022

Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

October 26, 2022

Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims

October 23, 2022

Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8: 00 a.m. ET

October 18, 2022

Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film

October 10, 2022

Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets

September 27, 2022

Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

September 26, 2022

Aquestive Therapeutics Announces Expert Allergy Scientific Advisory Board

September 11, 2022

Aquestive Therapeutics to Participate in Two Investor Conferences in September

August 30, 2022

Aquestive Therapeutics Receives FDA Tentative Approval for Libervant™ (diazepam) Buccal Film

August 30, 2022

Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

August 9, 2022

Aquestive Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 1, 2022

Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference

July 25, 2022

Aquestive Therapeutics to Report Second Quarter 2022 Financial Results and Recent Business Highlights on August 2 and Host Conference Call on August 3 at 8: 00 a.m. ET

July 19, 2022

Aquestive Therapeutics Reports Positive Results from Final Two Arms of EPIPHAST Trial Supporting Performance and Real-World Functionality of AQST-109 Epinephrine Oral Film

July 10, 2022

Aquestive Therapeutics Reports Positive Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

June 14, 2022

Aquestive Therapeutics to Participate in JMP Securities Life Sciences Conference

June 6, 2022

Aquestive Therapeutics, Inc. Announces $8.5 Million Registered Direct Offering

June 5, 2022

Aquestive Therapeutics Announces CEO Transition

May 16, 2022

Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference

May 9, 2022

Aquestive Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 2, 2022

Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8: 00 a.m. ET

April 17, 2022

Aquestive Therapeutics Announces Common Stock Purchase Agreement for up to $40 Million with Lincoln Park Capital

April 12, 2022

Aquestive Therapeutics Reports Positive Topline Data from Part 2 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

April 11, 2022

Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis

March 16, 2022

Aquestive Therapeutics Reports Full Year 2021 Results Exceeding Revenue and EBITDA Guidance

March 7, 2022

Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China

March 2, 2022

Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

February 27, 2022

Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film

February 24, 2022

Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film

February 23, 2022

Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8: 00 a.m. ET

February 21, 2022

Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

January 6, 2022

Calls in 2022

Decks in 2022